Pasireotide (SOM230)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Tumors
Conditions
Carcinoid Tumors
Trial Timeline
Jan 1, 2004 → Jul 1, 2008
NCT ID
NCT00088595About Pasireotide (SOM230)
Pasireotide (SOM230) is a phase 2 stage product being developed by Novartis for Carcinoid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00088595. Target conditions include Carcinoid Tumors.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00994110 | Phase 3 | Completed |
| NCT00088595 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoid Tumors